CIPLA LTD.

Cipla Ltd announced that its Board of Directors, in a meeting held on July 23, 2026, has approved changes in Key Managerial Personnel (KMPs) and authorized officers under SEBI Listing Regulations. These changes are effective from July 24, 2026. The disclosure includes updated contact details for key individuals such as the Managing Director and Global CEO, Global CFO, Company Secretary, and Chief General Counsel. The board meeting commenced at 9:15 a.m. IST and concluded at 1:00 p.m. IST. This information is also available on the company's website.

Cipla Ltd announced grants under its Employee Stock Option Scheme 2013-A (ESOS 2013-A) and Cipla Employee Stock Appreciation Rights Scheme 2021 (ESAR 2021). Under ESOS 2013-A, 5,530 stock options were granted with a 2-year vesting period and a 5-year exercise period from vesting. Under ESAR 2021, 19,179 Employee Stock Appreciation Rights were granted with a 3-year graded vesting and a 5-year exercise period from vesting. The exercise price for stock options is INR 2, and for ESARs is INR 2 per equity share. The company's board meeting, which commenced today, has concluded.

Cipla Ltd announced that its Board of Directors, in a meeting held on July 23rd, 2026, approved a change in the reporting structure for Mr. Sanjay Joseph, Head – API Business. Consequently, Mr. Joseph will cease to be classified as Senior Managerial Personnel (SMP) effective July 24th, 2026. This change is due to a shift in his reporting line within the company. Further details as required by SEBI Listing Regulations are provided in Annexure A.

Cipla Ltd announced a change in its Chief Financial Officer role. Mr. Ashish Adukia, the Global Chief Financial Officer, will transition to an internal business leadership role, relinquishing his CFO position and KMP status effective close of business on July 23, 2026. Concurrently, Mr. Dinesh Jain, currently Chief – Corporate Finance, has been appointed as the new Global Chief Financial Officer and KMP, effective July 24, 2026. Mr. Jain brings over three decades of experience in strategic planning and corporate finance.

Cipla Ltd announced a significant change in its finance leadership following a Board meeting held on July 23, 2026. Mr. Ashish Adukia has transitioned from his role as Global Chief Financial Officer (CFO) and Key Managerial Personnel (KMP) to an internal business leadership role, effective close of business hours on July 23, 2026. Concurrently, Mr. Dinesh Jain, currently Chief – Corporate Finance, has been appointed as the new Global CFO and KMP, effective July 24, 2026. Mr. Jain brings over three decades of experience in strategic planning, corporate finance, and business valuation.

Cipla Limited announced its unaudited consolidated financial results for the quarter ended June 30th, 2026 (Q1FY27). The company reported global revenues of INR 7,119 Cr, with a Profit After Tax (PAT) of INR 789 Cr. The One-India business showed strong performance with 12% YoY growth, driven by improved chronic mix to 60.4%. North America contributed $162 Mn in revenue, with new product launches including gVentolin, Nintedanib, and Dapagliflozin. The Emerging Markets and Europe segment grew 5% YoY in USD terms. R&D investments stood at INR 486 Cr, representing 6.8% of sales. The company maintained a strong net cash position of INR 9,494 Cr.

Cipla opened FY27 with a soft print as consolidated net profit fell 39.2% year-on-year to ₹785.55 Cr (from ₹1,291.61 Cr in Q1 FY26) on near-flat revenue of ₹7,119.28 Cr (+2.3% YoY). The headline QoQ optics look strong — PAT up 44.8% and revenue up 8.8% — but that is off a weak Q4 FY26 base (₹542.51 Cr PAT, dented by an impairment) and is not the story; the year-on-year comparison is, and it is a clear step down against a very strong year-ago quarter. The damage is entirely at the margin line. EBITDA margin compressed to ~16.8% from 25.6% a year ago, and net margin fell to 11.0% from 17.9%, as the high-margin US portfolio rolled off — the loss of generic Revlimid revenue and the absence of Lanreotide supplies, exactly the headwinds brokerages had flagged. Cost of materials and purchases held broadly flat but employee cost (₹1,497 Cr, +14% YoY) and depreciation (₹304 Cr, +20% YoY) rose, so the operating deleverage on a flat topline drove the profit fall. There was no exceptional item this quarter, so the drop is clean and operational rather than accounting-driven — unlike FY26, which carried a ₹275.91 Cr labour-code charge. The result missed the street: Nuvama had modelled revenue +5.9% and PAT −30.7% YoY, and Motilal Oswal expected US sales down ~28%; Cipla came in weaker on both topline (+2.3%) and bottom line (−39%). Against management's own FY27 guidance — EBITDA margin of 18.5–20% with an explicitly H2-weighted, new-launch-driven ramp, a $1bn US run-rate by FY27-end (excluding Lanreotide), and market-beating double-digit India growth — Q1's ~16.8% margin runs below the band but is consistent with the guided back-ended shape; the guidance is intact but now visibly H2-dependent. Concurrent corporate developments this quarter were largely governance/housekeeping (90th AGM, appointment of B S R & Co. as statutory auditor, one USFDA observation at a subsidiary, an ESG rating revised down to 64) and did not move the numbers. Standalone PAT of ₹862.16 Cr exceeded consolidated, reflecting a ₹34.33 Cr aggregate net loss across the overseas/subsidiary base.

Cipla Ltd announced that its wholly-owned subsidiary, InvaGen Pharmaceuticals Inc., located in Long Island, New York, underwent a routine current Good Manufacturing Practices (cGMP) inspection by the United States Food and Drug Administration (USFDA). The inspection took place from July 13th to July 17th, 2026. Upon conclusion, the facility received one observation in Form 483. Cipla has stated its commitment to working closely with the USFDA and addressing the observation comprehensively within the stipulated timeframe.

Cipla Ltd has announced its ESG ratings received from Crisil ESG Ratings & Analytics Limited. The company was assigned a 'Crisil ESG 69' rating and a 'Crisil Core ESG 66' rating. This disclosure is made pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The communication from Crisil was received on July 11, 2026. This information is for record purposes.

Cipla Ltd has issued a clarification regarding its 90th Annual General Meeting (AGM) transcript, originally filed on July 3rd, 2026. The company identified inadvertent typographical errors in the initial transcript and is now providing a corrected version. The filing details the presence of key board members and management, including Dr. Y. K. Hamied (Non-Executive Chairman), Mr. Achin Gupta (Managing Director & Global CEO), and Mr. Ashish Adukia (Global CFO), along with statutory auditors and other representatives. The AGM was conducted via video conferencing on June 25th, 2026.